Close

News

Code Pharma BV: Antiviral Drug Codivir Shows Promising Effect Against COVID-19

Codivir, a short synthetic 16 amino-acid peptide, derived from the HIV-1 integrase, was originally discovered at the Hebrew University in Israel. Code Pharma discovered that the peptide had a direct antiviral effect against SARS-CoV-2, the novel Coronavirus causing COVID-19. In-vitro...

NRx’s Zyesami lowers respiratory distress in Phase IIb/III Covid-19 trial

NRx Pharmaceuticals has reported additional data from Phase IIb/III clinical trial where its drug, Zyesami (aviptadil), offered a rise in blood oxygen within a day in critical Covid-19 patients with acute respiratory failure. Zyesami is a synthetic form of vasoactive...

Virpax Inks MMS019 Manufacturing and Supply Agreement

Virpax Pharmaceuticals, a company specializing in developing product candidates for pain management, CNS and anti-viral indications, has entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide...

Quotient Sciences Invests in Drug Substance Manufacturing Facility

Quotient Sciences, a drug development and manufacturing company, is investing £6.3 million pounds ($8.6mn) in its recently acquired manufacturing facility in Alnwick, UK. The investment will expand Quotient’s drug substance manufacturing capability and will create 80 new jobs over...

Innovent Biologics, Bolt Biotherapeutics Enter Immuno oncology Alliance

Innovent Biologics, Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines for cancer, metabolic, autoimmune and other diseases, and Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents, entered a collaboration to research...

SK bioscience & GSK initiate phase 3 trial of adjuvanted Covid-19 vaccine candidate

SK bioscience (SK) and GlaxoSmithKline (GSK) announced the initiation of a phase 3 clinical study of SK’s Covid-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim phase 1/2 results. The randomised, active-controlled global trial will enroll...

Abbott introduces single-dose formulation of carbetocin for prevention of postpartum haemorrhage in India

Abbott, the global healthcare company has announced the introduction of a room-temperature-stable, single-dose formulation of carbetocin in India, which is available in convenient vials, to help in the prevention of postpartum haemorrhage (PPH). Abbott’s product is available in the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »